HMGCR rs17244841: Statin Response Variant
This variant in the HMGCR gene is a genetic marker investigated for its potential role in how individuals respond to cholesterol-lowering statin medications. Scientific research explores how this specific change in the genetic code may correlate with differences in lipid-lowering efficacy among patients.
What each genotype means
Increased statin response
Research suggests that individuals with this genotype may experience a more robust reduction in LDL-cholesterol levels when treated with statin medications. This variant is part of a haplotype associated with how the body processes cholesterol-lowering therapy. Please discuss your specific medication response and any necessary dosing adjustments with your clinician or pharmacist.
This is the more common genotype for this variant in many populations.
Reduced statin response
Studies indicate that carriers of this genotype may show a reduced LDL-cholesterol lowering response to statin treatment compared to those without the T allele. This variant is often studied as part of a specific genetic haplotype linked to statin efficacy. Please consult your healthcare provider or pharmacist to review your treatment plan and medication effectiveness.
This genotype is observed at a lower frequency than the homozygous A genotype in most studied populations.
Reduced statin response
Individuals with this genotype may experience a less pronounced decrease in LDL-cholesterol levels when taking statins. This association is linked to a specific genetic haplotype in the HMGCR gene that influences how patients respond to these medications. You should discuss your cholesterol management and medication response with your doctor or pharmacist to ensure your treatment is optimized.
This is the least common genotype for this variant, occurring in a small percentage of the population.
Understanding rs17244841 and the HMGCR Gene
The variant rs17244841 is a single nucleotide polymorphism (SNP) located within the HMGCR gene. This gene provides instructions for making the enzyme HMG-CoA reductase, which plays a central role in the body’s production of cholesterol. By regulating the rate-limiting step of the mevalonate pathway, the HMGCR enzyme is the primary biological target of statin drugs. Statins work by inhibiting this enzyme, thereby reducing the amount of cholesterol produced by the liver. Because this gene is the direct site of action for these medications, researchers study variants within the HMGCR region to determine if subtle genetic differences influence the body's sensitivity to treatment. Located on chromosome 5, this SNP is one of many genetic markers scientists evaluate to better understand the variability in how patients manage their cholesterol levels when prescribed standard therapeutic interventions.
The Science of Statin Response Associations
Research into rs17244841 focuses on pharmacogenomics—the study of how genes affect a person’s response to drugs. Multiple studies in the GWAS Catalog and Pharmacogenomics Knowledge Base (PharmGKB) have examined whether this variant influences how much a patient's low-density lipoprotein (LDL) cholesterol levels drop after starting statin therapy. While some clinical studies have suggested that specific HMGCR variants can influence lipid-lowering outcomes, the evidence for rs17244841 is currently considered moderate. It is important to recognize that cholesterol levels are a complex trait influenced by many factors, including dozens of other genetic variants, diet, physical activity, and overall health status. Because multiple genes and environmental factors are involved, this single SNP is unlikely to be the sole determinant of a patient's drug response. Ongoing research continues to refine our understanding of how this marker fits into the broader picture of cardiovascular health and personalized medicine.
Population Frequency and Distribution
Data from the gnomAD database indicate that rs17244841 is a relatively uncommon variant in the general population, with a Global Minor Allele Frequency (GMAF) of approximately 0.038. This frequency is not uniform across all ancestral groups; population genetics often show variations in the prevalence of specific alleles depending on geographic and ancestral backgrounds. For example, the frequency may differ between populations of European, African, East Asian, and South Asian descent. Because the variant is relatively rare, the number of individuals who carry two copies of the minor allele is small, which can make it more challenging for researchers to draw definitive, large-scale conclusions about its clinical impact. As with many pharmacogenetic markers, these frequency differences underscore the importance of conducting research across diverse human populations to ensure that findings are applicable to a wide range of patients worldwide.
Navigating Your Genetic Information
It is critical to understand that the presence of the rs17244841 variant is not a diagnostic test, nor should it be used to make independent medical decisions. If you have received information about this genotype, it is meant for educational purposes rather than clinical guidance. Statin response is influenced by a complex interplay of genetics, lifestyle, and other medications. If you are concerned about the effectiveness of your cholesterol-lowering treatment, you should discuss this directly with your physician or a clinical pharmacist. They can assess your complete medical history, review your current cholesterol levels, and determine if any changes to your treatment plan are necessary. Never stop taking a prescribed medication or adjust your dosage without consulting a healthcare professional. By engaging in a conversation with your care team, you can ensure that your treatment is tailored to your specific clinical needs rather than relying on a single genetic data point.
How common is this variant?
Data from the gnomAD database indicate that rs17244841 is a relatively uncommon variant in the general population, with a Global Minor Allele Frequency (GMAF) of approximately 0.038.
Frequently asked questions
Does this variant mean statins won't work for me?
No. This variant is only one of many factors that can influence how your body responds to statins. Whether a medication is effective depends on your overall genetic profile, diet, exercise, and other health variables, not just this single SNP.
Can I use this SNP to choose the right statin?
Currently, there is no clinical consensus or guideline using rs17244841 to select a specific type or dose of statin. Decisions about your medication should be based on your cholesterol panels and clinical evaluation by your doctor.
Should I get a DNA test to check for this variant?
There is no medical necessity to specifically test for this variant. Routine cholesterol monitoring through blood tests is the standard and most reliable way to determine if your medication is working effectively.
Is this variant related to statin side effects?
Research primarily associates this variant with the lipid-lowering response (how much cholesterol is reduced). Evidence linking this specific SNP to statin side effects, such as muscle pain, is not established.
Sources & further reading
Educational information only, last refreshed 9/21/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs17244841?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29